Vancomycin

Generic Name: Vancomycin

Brand Names: Firvanq, Vancocin

Drug Type: Small Molecule

Chemical Formula: C_₆₆H_₇₅Cl_₂N_₉O_₂₄

CAS Number: 1404-90-6

Unique Ingredient Identifier: 6Q205EH1VU

Background: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Indication: Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

Associated Conditions: Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection

Associated Therapies: -

Clinical Trials

AbioKin - Antibiotic Kinetics

Completed

Conditions: Infection
Critical Illness

Interventions: Drug: Piperacillin-tazobactam combination product
Drug: Linezolid
Drug: Meropenem
Drug: Vancomycin

First Posted Date: 2015-11-20

Last Posted Date: 2021-01-19

Lead Sponsor: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva

Target Recruit Count: 1500

Registration Number: NCT02609646

Locations: 🇮🇹
Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione, Firenze, FI, Italy
🇮🇹
Ospedale San Giovanni di Dio, Orbetello, Grosseto, Italy
🇮🇹
Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1, Lecco, Lombardia, Italy

and more 8 locations

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

Phase 3

Completed

Conditions: Skin Structures and Soft Tissue Infections

Interventions: Drug: Iclaprim
Drug: Vancomycin

First Posted Date: 2015-11-18

Last Posted Date: 2018-08-07

Lead Sponsor: Motif Bio

Target Recruit Count: 613

Registration Number: NCT02607618

Locations: 🇺🇸
St. Mary Medical Center ER, Long Beach, California, United States
🇺🇸
California, Long Beach, California, United States
🇺🇸
Georgia, Columbus, Georgia, United States

and more 16 locations

Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients

Phase 4

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Placebo
Drug: Vancomycin

First Posted Date: 2015-11-16

Last Posted Date: 2015-11-16

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT02605213

Locations: 🇮🇷
Imam khomeini Hospital Complex, Tehran, Iran, Islamic Republic of

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

Phase 3

Completed

Conditions: Skin Structures and Soft Tissue Infections

Interventions: Drug: vancomycin
Drug: iclaprim

First Posted Date: 2015-11-09

Last Posted Date: 2018-06-19

Lead Sponsor: Motif Bio

Target Recruit Count: 600

Registration Number: NCT02600611

Locations: 🇺🇸
Nebraska, Lincoln, Nebraska, United States
🇺🇸
Florida, Miami, Florida, United States
🇺🇸
Washington, Seattle, Washington, United States

and more 14 locations

Intracameral Antibiotic Safety Study

Phase 3

Suspended

Conditions: Vancomycin
Moxifloxacin
Intracameral Antibiotics
Cataract Surgery
Phacoemulsification
Endophthalmitis

Interventions: Drug: Placebo
Drug: Vancomycin
Drug: Moxifloxacin

First Posted Date: 2015-10-29

Last Posted Date: 2022-04-27

Lead Sponsor: Panhandle Eye Group, LLP

Target Recruit Count: 500

Registration Number: NCT02590523

Locations: 🇺🇸
Rush Eye, Amarillo, Texas, United States

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Phase 4

Completed

Conditions: Staphylococcal Skin Infections
Skin Diseases, Infectious

Interventions: Drug: Ceftaroline
Drug: Vancomycin

First Posted Date: 2015-10-21

Last Posted Date: 2016-11-01

Lead Sponsor: Wayne State University

Target Recruit Count: 174

Registration Number: NCT02582203

Locations: 🇺🇸
St. John Hospital and Medical Center, Detroit, Michigan, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Detroit Medical Center, Detroit, Michigan, United States